Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Burkitt Lymphoma
Drug:
Rituxan (rituximab)
(
CD20 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
European Medicines Agency
Excerpt:
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with...Burkitt lymphoma (BL)…
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Burkitt Lymphoma: Induction therapy <60 y…cytarabine + rituximab (regimen includes intrathecal therapy)
Secondary therapy:
cytarabine
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login